HomeCompareBDGIF vs ABBV

BDGIF vs ABBV: Dividend Comparison 2026

BDGIF yields 1.22% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $75.3K in total portfolio value
10 years
BDGIF
BDGIF
● Live price
1.22%
Share price
$44.31
Annual div
$0.54
5Y div CAGR
25.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.0K
Annual income
$1,515.86
Full BDGIF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BDGIF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDGIFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDGIF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDGIF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDGIF
Annual income on $10K today (after 15% tax)
$103.46/yr
After 10yr DRIP, annual income (after tax)
$1,288.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $19,767.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDGIF + ABBV for your $10,000?

BDGIF: 50%ABBV: 50%
100% ABBV50/50100% BDGIF
Portfolio after 10yr
$64.7K
Annual income
$13,143.81/yr
Blended yield
20.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BDGIF
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
3.5
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDGIF buys
0
ABBV buys
0
No recent congressional trades found for BDGIF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDGIFABBV
Forward yield1.22%3.06%
Annual dividend / share$0.54$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25.4%40.6%
Portfolio after 10y$27.0K$102.3K
Annual income after 10y$1,515.86$24,771.77
Total dividends collected$6.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: BDGIF vs ABBV ($10,000, DRIP)

YearBDGIF PortfolioBDGIF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,853$152.63$11,550$430.00$697.00ABBV
2$11,806$194.13$13,472$627.96$1.7KABBV
3$12,880$247.51$15,906$926.08$3.0KABBV
4$14,098$316.46$19,071$1,382.55$5.0KABBV
5$15,491$405.95$23,302$2,095.81$7.8KABBV
6$17,098$522.76$29,150$3,237.93$12.1KABBV
7$18,972$676.21$37,536$5,121.41$18.6KABBV
8$21,179$879.31$50,079$8,338.38$28.9KABBV
9$23,812$1,150.42$69,753$14,065.80$45.9KABBV
10$26,995$1,515.86$102,337$24,771.77$75.3KABBV

BDGIF vs ABBV: Complete Analysis 2026

BDGIFStock

Badger Infrastructure Solutions Ltd. provides non-destructive excavating and related services in Canada and the United States. Its Badger Hydrovac technology uses a pressurized water stream to liquify the soil cover. The company offers daylighting, potholing, and power distribution services for visual confirmation of buried lines, directional drilling test holes, sacrificial anode installation, pipeline and utility crossings, and subsurface utility engineering test holes applications; and debris removal services for frac tank clean-outs, road and box culvert clean-outs, pipe-rammed casing clean-outs, ballast and filter media removal, and inside structures and buildings material removal. It also provides pipeline excavation services for pipeline crossing and tie-in, hydro probing, utility conflict, and oil and fuel spill applications; and service repair pits for gas service tie-in, electric cable fault repair, water main and service repair, and telecom splice applications. In addition, the company offers anode installation, shoring installation, and tank cleanouts services; trenching services for slot trenching, expose existing cables or conduits, drain tile installation, and line fault repairs; and pole and piling holes services for utility, traffic signal, transmission pole holes, light standard and sign post holes, pole removals, end-bearing, pilot holes for friction, spread footing piles, and well monitor installations applications. It is also involved in air and mandrel testing, CCTV inspections, laser profiling, flushing & cleaning, mainline to lateral line inspections, reaming and concrete removal, sewer and main line locating, and smoke testing sewer services, as well as responding to disasters and locating solutions. The company was formerly known as Badger Daylighting Ltd. and changed its name to Badger Infrastructure Solutions Ltd. in May 2021. Badger Infrastructure Solutions Ltd. was founded in 1992 and is based in Calgary, Canada.

Full BDGIF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BDGIF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDGIF vs SCHDBDGIF vs JEPIBDGIF vs OBDGIF vs KOBDGIF vs MAINBDGIF vs JNJBDGIF vs MRKBDGIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.